| Bioactivity | T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase[1][2]. | ||||||||||||
| Target | EC50: 17 μM (parainfluenza-3 virus); EC50: 24 μM (Punta Toro virus) .EC50: 97.5 μM (ZIKV strain SZ01) | ||||||||||||
| Invitro | T-1105 has antiviral activity against various RNA viruses, including Zika virus (ZIKV), influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), and foot-and-mouth disease virus (FMDV)[1][2]. T-1105 has good anti-RNA virus activity with values EC50 of 17 μM and 24 μM for parainfluenza-3 virus and Punta Toro virus in MDCK cells[3].T-1105 is a potential inhibitor of Zika virus replication[4].T-1105 can inhibit the SFTSV replication with an value IC50 of 49 μM in Vero cells and is not affect cell viability in 0-3 μM[5]. Cell Cytotoxicity Assay[4] Cell Line: | ||||||||||||
| In Vivo | T-1105 (Oral, 200 mg/kg, twice daily for 6 days) effectively inhibits the virus replication in the infected pigs[6]. Animal Model: | ||||||||||||
| Name | T-1105 | ||||||||||||
| CAS | 55321-99-8 | ||||||||||||
| Formula | C5H5N3O2 | ||||||||||||
| Molar Mass | 139.11 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Huchting J, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5. [2]. Furuta Y, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102. [3]. Johanna Huchting, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5. [4]. Lei Cai, et al. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 2017 Sep;162(9):2847-2853. [5]. Hideki Tani, et al. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus. [6]. Yousuke Furuta, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102. |